Antibody Drug Conjugates Market to Reach $37.5 Billion by 2035
Antibody drug conjugates market was valued at $14.2 billion in 2025 and is projected to reach $37.5 billion by 2035, growing at a CAGR of 10.3% during the forecast period (2026-2035). The primary factor supporting expansion of the antibody drug conjugates market is the sustained rise in cancer incidence across major healthcare systems, creating strong demand for advanced targeted treatment options. According to the World Health Organization and the International Agency for Research on Cancer (IARC), approximately 20 million new cancer cases and 9.7 million cancer deaths were recorded in 2022. The same agencies project that annual new cancer cases will increase to more than 35 million by 2050, reflecting a 77% rise from 2022 levels. This sharp increase is expanding the addressable patient population for oncology therapeutics, particularly in breast cancer, lung cancer, gastric cancer, and urothelial cancer where antibody drug conjugates are already clinically established. Hospitals and oncology centers are increasingly prioritizing therapies that improve efficacy while reducing systemic toxicity. ADCs are well positioned in this shift because they selectively deliver cytotoxic payloads to tumor cells. Rising patient volumes and broader treatment eligibility continue to support revenue growth across approved products.
Browse the full report description of “Antibody Drug Conjugates Market Size, Share & Trends Analysis Report by Antibody Type (Monoclonal Antibody-Based ADCs, Bispecific Antibody-Based ADCs, and Fragment/Engineered Antibody-Based ADCs), by Target Antigen (HER2, CD19, CD22, CD30, TROP2, BCMA, Nectin-4, and Others), by Indication (Breast Cancer, Lung Cancer, Urothelial Cancer, Gastric Cancer, Ovarian Cancer, Cervical Cancer, and Other), by End User (Hospitals, Cancer Specialty Centers, Academic & Research Institutes, Contract Research Organizations (CROs), and Biopharmaceutical Companies), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/antibody-drug-conjugates-market
The market is also being strengthened by the transition toward biomarker-led treatment models and precision medicine pathways. Many high-incidence cancers now require HER2, TROP2, Nectin-4, or other antigen testing before therapy selection, directly supporting demand for ADC products linked to these targets. IARC data shows that lung cancer accounted for 2.5 million new cases in 2022, while female breast cancer represented 2.3 million new cases, making them among the largest oncology indications globally. These are also two of the most commercially significant therapeutic areas for antibody drug conjugates. Regulatory agencies are approving broader labels for earlier-line treatment settings, increasing patient access and duration of therapy use. Pharmaceutical companies are expanding investment in next-generation payloads, bispecific formats, and combination regimens, reinforcing long-term product adoption. As clinical outcomes improve and precision diagnostics become more routine, antibody drug conjugates are expected to capture a larger share of oncology drug spending over the forecast period.
Innovation Leaders Transforming the Antibody Drug Conjugates Market
The key players in the antibody drug conjugates market include AstraZeneca PLC, Daiichi Sankyo Company, Limited, F. Hoffmann-La, Roche Ltd, Pfizer Inc., Gilead Sciences, Inc, among others. These companies are advancing innovation in antibody drug conjugate therapies through the development of highly selective targeting antibodies, improved linker technologies, and potent cytotoxic payload platforms, enabling precise cancer treatment with enhanced therapeutic efficacy and reduced systemic toxicity while supporting growing demand for advanced oncology care and next-generation targeted medicines.
- In April 2026, Eli Lilly and Company strengthened its oncology pipeline through the acquisition of CrossBridge Bio, gaining access to a next-generation dual-payload antibody drug conjugate platform originally developed at UTHealth Houston.
- In October 2025, Datroway, another ADC from AstraZeneca PLC and Daiichi Sankyo Company, Limited, reported improved phase 3 results in first-line triple-negative breast cancer settings, strengthening the competitive ADC pipeline.
Market Coverage
- The market number available for – 2025-2035
- Base year- 2025
- Forecast period- 2026-2035
- Segment Covered-
- By Antibody Type
- By Target Antigen
- By Indication
- By End User
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape - AstraZeneca PLC, Daiichi Sankyo Company, Limited, F. Hoffmann-La, Roche Ltd, Pfizer Inc., Gilead Sciences, Inc,, among others.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Antibody Drug Conjugates Market Report Segment
By Antibody Type
- Monoclonal Antibody-Based ADCs
- Bispecific Antibody-Based ADCs
- Fragment/Engineered Antibody-Based ADCs
By Target Antigen
- HER2
- CD19
- CD22
- CD30
- TROP2
- BCMA
- Nectin-4
- Others
By Indication
- Breast Cancer
- Lung Cancer
- Urothelial Cancer
- Gastric Cancer
- Ovarian Cancer
- Cervical Cancer
- Other
By End User
- Hospitals
- Cancer Specialty Centers
- Academic & Research Institutes
- Contract Research Organizations (CROs)
- Biopharmaceutical Companies
Global Antibody Drug Conjugates Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- ASEAN Economies
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/antibody-drug-conjugates-market